Abstract
Prior to the discovery of cyclooxygenase-2 (COX-2), a beneficial association was shown between chronic usage of non steroidal anti-inflammatory drugs (NSAIDs), that nonselectively inhibit both cyclooxygenase-1 (COX-1) and COX-2, and prevention of colorectal cancer. The cloning of COX-2 allowed the development of enzyme inhibitors that selectively inhibit COX-2 and also facilitated the expression profiling of COX-2 in many cancer tissues. COX-2 selective inhibitors have shown efficacy in vitro and in vivo in several animal cancer models and in limited human clinical trials. The potency of COX-2 inhibitors in vivo can be attributed to the inhibition of the enzyme in the tumor as well as in stromal cells, resulting in reduction of carcinogen production, anti-proliferative and pro-apoptopic actions within the tumor and anti-angiogenic and pro-immune surveillance activities in endothelial and myeloid cells. The combination of COX-2 inhibitor with standard cancer chemotherapeutic and / or radiation may provide additional therapeutic paradigms in the treatment of various human cancers.
Keywords: colorectal cancer, prostaglandins, nsaid, cyclooxygenase, cox, cancer, cox-2 inhibitors, angiogenesis
Current Pharmaceutical Design
Title: Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Volume: 10 Issue: 6
Author(s): J. F. Evans and S. L.. Kargman
Affiliation:
Keywords: colorectal cancer, prostaglandins, nsaid, cyclooxygenase, cox, cancer, cox-2 inhibitors, angiogenesis
Abstract: Prior to the discovery of cyclooxygenase-2 (COX-2), a beneficial association was shown between chronic usage of non steroidal anti-inflammatory drugs (NSAIDs), that nonselectively inhibit both cyclooxygenase-1 (COX-1) and COX-2, and prevention of colorectal cancer. The cloning of COX-2 allowed the development of enzyme inhibitors that selectively inhibit COX-2 and also facilitated the expression profiling of COX-2 in many cancer tissues. COX-2 selective inhibitors have shown efficacy in vitro and in vivo in several animal cancer models and in limited human clinical trials. The potency of COX-2 inhibitors in vivo can be attributed to the inhibition of the enzyme in the tumor as well as in stromal cells, resulting in reduction of carcinogen production, anti-proliferative and pro-apoptopic actions within the tumor and anti-angiogenic and pro-immune surveillance activities in endothelial and myeloid cells. The combination of COX-2 inhibitor with standard cancer chemotherapeutic and / or radiation may provide additional therapeutic paradigms in the treatment of various human cancers.
Export Options
About this article
Cite this article as:
Evans F. J. and Kargman L.. S., Cancer and Cyclooxygenase-2 (COX-2) Inhibition, Current Pharmaceutical Design 2004; 10 (6) . https://dx.doi.org/10.2174/1381612043453126
| DOI https://dx.doi.org/10.2174/1381612043453126 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods
Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention
Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and ...read more
Mapping Dynamic Sites and Designing Novel Therapeutics
The concept of allostery, where ligand binding at a site distinct from the active or orthosteric site modulates protein function, has emerged as a transformative paradigm in modern drug discovery. Unlike conventional orthosteric drugs that often face limitations in selectivity and off-target effects, allosteric modulators offer a promising alternative. Their ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Antioxidant Properties and Associated Mechanisms of Salicylates
Current Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Cytosporones and Related Compounds, A Review: Isolation, Biosynthesis, Synthesis and Biological Activity of Promising Fungal Resorcinolic Lipids
Current Organic Synthesis Current Progress in Targeting Telomere and Telomerase Enzymes for the Treatment of Cancer
Current Cancer Therapy Reviews Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Current Diabetes Reviews γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Current Approaches to Glycoprotein Analysis
Protein & Peptide Letters Docking Studies for Multi-Target Drugs
Current Drug Targets Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Current Genomics Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Atrial Natriuretic Peptide: A Magic Bullet for Cancer Therapy Targeting Wnt Signaling and Cellular pH Regulators
Current Medicinal Chemistry





